OKYO Pharma

OKYO · NASDAQ

$1.37−$0.03 (−2.14%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $1.40

About OKYO

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Employees: 4
Headquarters: London
Listed: Jul 17, 2018
Sector: Health Care
Industry: Biotechnology
Website: okyopharma.com

Leadership

OKYO Pharma executives
Name	Title	Since	Age
Gabriele Cerrone	—	—	53
Gary Jacob	—	2021	78
Keeren Shah	—	—	49
Raj Patil	—	—	68
Willy Simon	—	—	74
John Brancaccio	—	—	77
Bernard Denoyer	—	—	78

Similar companies

Companies in the same industry as OKYO Pharma

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.